Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEli Lilly and Co. announced Thursday that it still expects its earnings per share to grow in the double-digit range through
2011 and added it plans to launch two new medicines per year starting in 2013.
The drugmaker expects to earn $4.65
to $4.85 per share in 2010, excluding the impact of health care reform and other items. On average, analysts expect income
of $4.74 per share, according to a survey by Thomson Reuters.
The Indianapolis-based company, which makes the anti-psychotic
Zyprexa and the antidepressant Cymbalta, said it has more than 60 molecules in clinical development, including 25 in mid and
late-stage development.
In August, Lilly debuted blood thinner Effient in the United States, the company’s first
new product launch since 2005.
Lilly’s fastest-growing product is Alimta, which saw its sales climb 47 percent
in the third quarter. Lilly said Thursday it plans to purse additional indications for the cancer drug, either as monotherapy,
or in combination with other oncolytics.
Earlier this year, the Indianapolis company said it would cut annual costs
by $1 billion by 2011 and produce new drugs faster.
Please enable JavaScript to view this content.